Skip to main content
. 2020 Feb 3;22(6):875–885. doi: 10.1093/neuonc/noaa016

Fig. 1.

Fig. 1

(A) OS and PFS distributions for eligible and evaluable PBTC-033 phase II patients (n = 50). (B) OS distributions for eligible and evaluable PBTC-033 phase II patients compared with PBTC historical controls. There was no evidence of a difference in survival between the patient groups (P = 0.46). (C) PFS by PAR level changes following veliparib treatment. (D) OS by PAR level changes after veliparib treatment.